drugset / Trial / NCT03666221
Nimotuzumab for Recurrent Nasopharyngeal Carcinoma
Phase 2
Unknown
67 enrolled
Fujian Cancer Hospital
Fujian Medical University Union Hospital · collabJiangxi Provincial Cancer Hospital · collabSun Yat-sen University · collabZhejiang Cancer Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The study assessed the clinical efficacy, and safety of the combination of Nimotuzumab administered concomitantly with intensity modulated radiation therapy(IMRT) in patients with recurrent nasopharyngeal cancer.
Timeline
- Start
- 2014-11-01
- Primary completion
- 2020-04-01
- Completion
- 2022-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nimotuzumab | Monoclonal antibody | 200 mg | — |